The Medicines CompanyMDCO announced that it has completed patient enrollment ahead of schedule in the phase III TANGO 1 study on one of its pipeline candidates, Carbavance (meropenem-vaborbactam), for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results